GLP-1s

Page 2 of 2

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By
January 22, 2025
Close up of RFK Jr. speaking against a blue background
Health

Health-care investors bank on Congress snarling RFK Jr.’s plans

By
January 17, 2025
Portrait of Crunch Fitness CEO Jim Rowley seated at Fortune's video studio.
Success

The CEO of Crunch Fitness doesn’t think there’s such a thing as work-life balance: ‘That’s for somebody who’s not fully committed’

By Jane Thier and Fortune Editors
January 16, 2025
A Walgreens store exterior with people walking by on the street
Retail

Walgreens CEO describes drawback of anti-shoplifting strategy: ‘When you lock things up…you don’t sell as many of them’

By
January 14, 2025

Most Popular